CEO Q&A: Dr. Aoife Brennan

By Dan Schell, Chief Editor, Clinical Leader

In our May 2019 issue, we featured Synlogic as our “Company To Watch,” and we interviewed Dr. Aoife Brennan, who has been president and CEO since May 2018. When we caught up with her in February 2021, she explained that, internally, the company is still focused on developing its “Synthetic Biotic” medicines for metabolic diseases, but it is also investigating ways to expand into other areas such as oncology and inflammatory bowel disease. For this Q&A, we wanted to find out how the past year had affected the company, both operationally and from a clinical trial standpoint.